Ultragenyx Reports Second Quarter 2021 Financial Results and Corporate Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/9/2026
- After-Hours Movers: COO, AEO, NAVN, AVAV, TORO
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
Ultragenyx Pharma (RARE) Misses Q2 EPS by 45c, Revenues Beat
August 2, 2021 4:31 PM EDTUltragenyx Pharma (NASDAQ: RARE) reported Q2 EPS of ($1.81), $0.45 worse than the analyst estimate of ($1.36). Revenue for the quarter came in at $87 million versus the consensus estimate of $85.03 million.
GUIDANCE:
Ultragenyx Pharma reaffirms FY2021 revenue of $180-190 million.
For earnings history and earnings-related data on Ultragenyx Pharma (RARE) click here.
... More